| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0891-5520(02)00012-0 |
| P698 | PubMed publication ID | 12371125 |
| P2093 | author name string | Jonathan Allen Cohn | |
| P2860 | cites work | The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals | Q28205170 |
| Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients | Q28375088 | ||
| HIV incidence among injecting drug users in New York City syringe-exchange programmes | Q30233828 | ||
| New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users | Q30573588 | ||
| Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective | Q30670433 | ||
| Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. | Q30730194 | ||
| HIV-1 RNA load in needles/syringes from shooting galleries in Miami: a preliminary laboratory report | Q30838130 | ||
| Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy | Q31705187 | ||
| Dynamics of behavioral risk factors for HIV/AIDS: a 6-year prospective study of injection drug users | Q31870967 | ||
| The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis | Q32027393 | ||
| Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection | Q32127288 | ||
| HIV-associated dementia: new insights into disease pathogenesis and therapeutic interventions | Q33664503 | ||
| Infection with GB virus C and reduced mortality among HIV-infected patients | Q34090499 | ||
| Management of psychiatric disorders in patients infected with human immunodeficiency virus | Q34340984 | ||
| Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice | Q34340996 | ||
| Needle-exchange attendance and health care utilization promote entry into detoxification | Q34506338 | ||
| Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial | Q35359761 | ||
| Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users | Q38503675 | ||
| Early neuropsychological impairment in HIV-seropositive intravenous drug users: evidence from the Italian Multicentre Neuropsychological HIV Study. | Q50900268 | ||
| Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. | Q51968509 | ||
| HIV infection and cognition in intravenous drug users: long-term follow-up. | Q52045311 | ||
| HIV transmission and the cost-effectiveness of methadone maintenance. | Q52278638 | ||
| Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users | Q52463049 | ||
| Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. | Q53322151 | ||
| Community support for needle exchange programs and pharmacy sale of syringes: a household survey in Baltimore, Maryland. | Q55067642 | ||
| Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. | Q55239798 | ||
| Serological pattern ?anti-HBc alone?: Report on a workshop | Q56439517 | ||
| Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users | Q57107985 | ||
| Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use | Q57259780 | ||
| Feasibility of an Emergency Department–Based, Risk-Targeted Voluntary HIV Screening Program | Q57433001 | ||
| HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic | Q58436580 | ||
| Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras | Q64133967 | ||
| Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men | Q70800782 | ||
| The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. WHO Multi-Centre Study of AIDS and Injecting Drug Use | Q72996654 | ||
| Lamivudine as initial treatment for chronic hepatitis B in the United States | Q73098368 | ||
| Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C | Q73485576 | ||
| Syringe prescription to prevent HIV infection in Rhode Island: a case study | Q73854869 | ||
| Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes | Q74002200 | ||
| High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study | Q74010685 | ||
| Physician prescribing of sterile injection equipment to prevent HIV infection: time for action | Q74039560 | ||
| High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen | Q74259952 | ||
| A multicentre study on the causes of death among Italian injecting drug users. AIDS has overtaken overdose as the principal cause of death | Q74425268 | ||
| Access to antiretroviral therapy in HIV-infected injection drug users | Q74485939 | ||
| Pharmacists' attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws | Q74776982 | ||
| Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men | Q77329127 | ||
| Survival of HIV-1 in syringes | Q77936968 | ||
| Lamivudine for chronic delta hepatitis | Q78045303 | ||
| Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users | Q39512038 | ||
| Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection | Q39526550 | ||
| Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS). | Q39551426 | ||
| Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. | Q39567699 | ||
| Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy | Q39571037 | ||
| Adherence to protease inhibitor therapy and outcomes in patients with HIV infection | Q39605935 | ||
| Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T cell decline and disease progression in injection drug users | Q39619651 | ||
| Medical care for injection-drug users with human immunodeficiency virus infection | Q40674545 | ||
| The Edinburgh cohort of HIV-positive injecting drug users at 10 years after infection: a case-control study of the evolution of dementia. | Q40944781 | ||
| The effect of syringe exchange use on high-risk injection drug users: a cohort study | Q41732202 | ||
| Variable progression of HIV-associated dementia | Q42456961 | ||
| A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 | ||
| Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? | Q42978018 | ||
| Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. | Q42980105 | ||
| Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. | Q42989119 | ||
| Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease | Q42994045 | ||
| Effect of coinfection with GB virus C on survival among patients with HIV infection | Q43034157 | ||
| Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin | Q43034568 | ||
| Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders | Q43035148 | ||
| Opiates as potential cofactors in progression of HIV-1 infections to AIDS. | Q43070988 | ||
| Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens | Q43541564 | ||
| HIV infection among patients in U.S. acute care hospitals. Strategies for the counseling and testing of the hospital patients. The Hospital HIV Surveillance Group | Q43610158 | ||
| Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy | Q43629454 | ||
| Access to medical care and service utilization among injection drug users with HIV/AIDS. | Q43685938 | ||
| Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS. | Q43878006 | ||
| The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state | Q44068644 | ||
| The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users | Q44095905 | ||
| Maintenance of HIV risk reduction among injection opioid users: a 12 month posttreatment follow-up | Q44346718 | ||
| The effect of drug-injection behavior on genetic evolution of HIV-1. | Q44599155 | ||
| Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection | Q44602591 | ||
| Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count | Q44641749 | ||
| Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users | Q45181474 | ||
| Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival | Q45334756 | ||
| Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection | Q45739024 | ||
| Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study | Q45739390 | ||
| Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load | Q45747378 | ||
| Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine | Q45747739 | ||
| Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee | Q45747996 | ||
| No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users | Q45750906 | ||
| Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group | Q45755649 | ||
| A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. | Q45761546 | ||
| Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. | Q45762651 | ||
| Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope | Q45771971 | ||
| Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group | Q45787461 | ||
| Effectiveness of psychosocial interventions in preventing HIV risk behaviour in injecting drug users | Q46086801 | ||
| HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement | Q48343313 | ||
| The Edinburgh cohort of HIV-positive drug users: pattern of cognitive impairment in relation to progression of disease | Q48426597 | ||
| Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. | Q50586398 | ||
| Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996. | Q50878662 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 745-770 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Infectious Disease Clinics of North America | Q15754797 |
| P1476 | title | HIV-1 infection in injection drug users | |
| P478 | volume | 16 |
| Q33688391 | Accelerated evolution of SIV env within the cerebral compartment in the setting of morphine-dependent rapid disease progression |
| Q40002439 | Analysis of the V1V2 region of the SIV envelope in the brains of morphine-dependent and control SIV/SHIV-infected macaques |
| Q33814884 | Associations among correlates of schedule adherence to antiretroviral therapy (ART): a path analysis of a sample of crack cocaine using sexually active African-Americans with HIV infection |
| Q44490716 | Co-occurring psychiatric symptoms and drug dependence or heavy drinking among HIV-positive people |
| Q24649164 | Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes |
| Q35243162 | From personal tragedy to personal challenge: responses to stigma among sober living home residents and operators |
| Q44362103 | HIV/AIDS risk among female sex workers who use crack in Southern Brazil. |
| Q35738878 | Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. |
| Q44924772 | Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir |
| Q28475509 | Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review |
| Q36311018 | Medical illness and comorbidities in drug users: implications for addiction pharmacotherapy treatment |
| Q28535281 | Primary drug-resistant tuberculosis in Hanoi, Viet Nam: present status and risk factors |
| Q34213818 | Short Communication: Lack of Immune Response in Rapid Progressor Morphine-Dependent and SIV/SHIV-Infected Rhesus Macaques Is Correlated with Downregulation of TH1 Cytokines |
| Q35282021 | Variable region 4 of SIV envelope correlates with rapid disease progression in morphine-exposed macaques infected with SIV/SHIV. |
Search more.